Onconephrology in the Era of Modern Cancer Therapy: Kidney Injury Associated with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have improved survival in many cancers, but they cause distinct types of kidney injury. This narrative review, based on a structured literature search, focuses on these two drug classes and is built around three clinical messages. The first is the renal-oncologic paradox: therapies that extend survival may leave a growing number of patients living with chronic kidney disease, so long-term renal follow-up is needed. The second is divergent management: ICI-associated acute kidney injury occurs in about 2–5% of treated patients, is usually acute tubulointerstitial nephritis, and is treated by withholding the ICI and giving corticosteroids. In contrast, kidney injury from VEGF-pathway inhibition is structural and hemodynamic (hypertension, proteinuria, podocytopathy, and thrombotic microangiopathy mainly with VEGF ligand blockade) and is managed with blood pressure control, renin–angiotensin system blockade, and dose modification rather than immunosuppression. The third is the role of cystatin C: creatinine-based eGFR can overestimate kidney function in patients with cachexia or sarcopenia, and cystatin C-based eGFR may improve the detection of kidney injury and drug dosing. We also briefly discuss emerging agents and patients with pre-existing chronic kidney disease.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-19
DOI
https://doi.org/10.3390/biomedicines14112682
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Onconephrology in the Era of Modern Cancer Therapy: Kidney Injury Associated with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Eun Jeong Ko, Sojung Youn, Ji Won Min, Seoree Kim et al.
Biomedicines
Acute Kidney Injury Research
article

Onconephrology in the Era of Modern Cancer Therapy: Kidney Injury Associated with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Eun Jeong Ko, Sojung Youn, Ji Won Min, Seoree Kim, Donghyuk Kang
article en

Abstract

Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have improved survival in many cancers, but they cause distinct types of kidney injury. This narrative review, based on a structured literature search, focuses on these two drug classes and is built around three clinical messages. The first is the renal-oncologic paradox: therapies that extend survival may leave a growing number of patients living with chronic kidney disease, so long-term renal follow-up is needed. The second is divergent management: ICI-associated acute kidney injury occurs in about 2–5% of treated patients, is usually acute tubulointerstitial nephritis, and is treated by withholding the ICI and giving corticosteroids. In contrast, kidney injury from VEGF-pathway inhibition is structural and hemodynamic (hypertension, proteinuria, podocytopathy, and thrombotic microangiopathy mainly with VEGF ligand blockade) and is managed with blood pressure control, renin–angiotensin system blockade, and dose modification rather than immunosuppression. The third is the role of cystatin C: creatinine-based eGFR can overestimate kidney function in patients with cachexia or sarcopenia, and cystatin C-based eGFR may improve the detection of kidney injury and drug dosing. We also briefly discuss emerging agents and patients with pre-existing chronic kidney disease.

BiomedicinesVol. 14(11)
The Catholic University of Korea Bucheon St. Mary's Hospital (KR), Catholic University of Korea (KR)
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon